Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model

被引:168
|
作者
Matosin, Natalie [1 ,2 ]
Halldorsdottir, Thorhildur [1 ]
Binder, Elisabeth B. [1 ,3 ]
机构
[1] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany
[2] Univ New South Wales, Fac Med, Sch Psychiat, Sydney, NSW, Australia
[3] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA
基金
欧洲研究理事会; 英国医学研究理事会; 美国国家卫生研究院;
关键词
Epigenetics; FKBP5; FKBP51; Gene by environment; Psychiatric disorders; Stress; EARLY-LIFE STRESS; GLUCOCORTICOID-RECEPTOR; MESSENGER-RNA; DEPRESSIVE SYMPTOMS; IMMUNOPHILIN FKBP51; FEAR EXTINCTION; CALCINEURIN INHIBITION; EPIGENETIC REGULATION; SIGNALING PATHWAY; DNA DEMETHYLATION;
D O I
10.1016/j.biopsych.2018.01.021
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Epidemiologic and genetic studies suggest common environmental and genetic risk factors for a number of psychiatric disorders, including depression, bipolar disorder, and schizophrenia. Genetic and environmental factors, especially adverse life events, not only have main effects on disease development but also may interact to shape risk and resilience. Such gene by adversity interactions have been described for FKBP5, an endogenous regulator of the stress-neuroendocrine system, conferring risk for a number of psychiatric disorders. In this review, we present a molecular and cellular model of the consequences of FKBP5 by early adversity interactions. We illustrate how altered genetic and epigenetic regulation of FKBP5 may contribute to disease risk by covering evidence from clinical and preclinical studies of FKBP5 dysregulation, known cell-type and tissue-type expression patterns of FKBP5 in humans and animals, and the role of FKBP5 as a stress-responsive molecular hub modulating many cellular pathways. FKBP5 presents the possibility to better understand the molecular and cellular factors contributing to a disease-relevant gene by environment interaction, with implications for the development of biomarkers and interventions for psychiatric disorders.
引用
收藏
页码:821 / 830
页数:10
相关论文
共 50 条
  • [1] Molecular Genetic and Epigenetic Mechanisms of FKBP5 Gene by Environment Interaction
    Klengel, Torsten
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S72 - S72
  • [2] Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism
    Zannas, A. S.
    Binder, E. B.
    GENES BRAIN AND BEHAVIOR, 2014, 13 (01) : 25 - 37
  • [3] Evidence Mounting for Gene-by-Environment Interactions at the FKBP5 Locus Predicting Psychiatric Symptoms
    Halldorsdottir, Thorhildur
    BIOLOGICAL PSYCHIATRY, 2016, 80 (11) : E89 - E91
  • [4] Molecular Mechanisms for Gene X Environment Interaction in Depression and Anxiety: Focus on FKBP5
    Binder, Elisabeth B.
    BIOLOGICAL PSYCHIATRY, 2013, 73 (09) : 244S - 244S
  • [5] Regulatory functions of FKBP5 intronic regions associated with psychiatric disorders
    Mendonca, Mariana S.
    Mangiavacchi, Paula M.
    Rios, Alvaro F. L.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 143 : 1 - 8
  • [6] FKBP5 Methylation, Psychiatric Disorders and Stress: A Systematic Review and Synthesis
    Izgi, Busra
    Kuvvet, Yasemin
    Musaoglu, Mirac Nur
    Cicek, Yusuf
    Oztosun, Cinar
    Eser, Hale Yapici
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S195 - S196
  • [7] Modulation of FKBP5 Gene By Environment Interaction by a Structural Variant
    Klengel, Torsten
    Binder, Elisabeth B.
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 290S - 291S
  • [8] Schizophrenia in the Spectrum of Gene-Stress Interactions: The FKBP5 Example
    Daskalakis, Nikolaos P.
    Binder, Elisabeth B.
    SCHIZOPHRENIA BULLETIN, 2015, 41 (02) : 323 - 329
  • [9] FKBP5 Allele-Specific Epigenetic Modification in Gene by Environment Interaction
    Torsten Klengel
    Elisabeth B Binder
    Neuropsychopharmacology, 2015, 40 : 244 - 246
  • [10] FKBP5 Allele-Specific Epigenetic Modification in Gene by Environment Interaction
    Klengel, Torsten
    Binder, Elisabeth B.
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 (01) : 244 - 246